日付	始値	高値	安値	終値	前日比	出来高	時価総額	25日乖離
2025
05/23	3,865	3,890	3,840	3,855	-0.26%	69,200	1846億9761万	+0.86%
05/22	3,850	3,885	3,840	3,865	-0.64%	55,800	1851億7673万	+1.36%
05/21	3,885	3,920	3,850	3,890	+0.13%	62,200	1863億7450万	+2.26%
05/20	3,930	3,935	3,870	3,885	-0.26%	65,400	1861億3495万	+2.51%
05/19	3,835	3,915	3,815	3,895	+2.37%	97,500	1866億1406万	+3.02%
05/16	3,820	3,860	3,770	3,805	+0.53%	93,400	1823億205万	+0.96%
05/15	3,780	3,820	3,760	3,785	+0.13%	69,900	1813億4383万	+0.58%
05/14	3,905	3,960	3,750	3,780	-4.06%	114,400	1811億427万	+0.64%
05/13	4,040	4,045	3,920	3,940	-2.11%	154,300	1887億7006万	+4.95%
05/12	4,110	4,135	3,925	4,025	-3.13%	161,100	1928億4251万	+7.42%
05/09	3,940	4,215	3,930	4,155	+4.53%	227,500	1990億7097万	+11.19%
05/08	16:00 2025年3月期決算説明会資料
05/08	10:00 自己株式立会外買付取引(ToSTNeT-3)による自己株式の取得結果及び自己株式の取得終了並びに自己株式の消却に関するお知らせ
05/08	4,200	4,200	3,880	3,975	+4.33%	659,300	1904億4696万	+6.77%
05/07	16:30 2025年3月期決算短信〔日本基準〕(連結)
05/07	16:30 2025年3月期決算補足資料
05/07	16:30 役員報酬制度の改定に関するお知らせ
05/07	16:30 剰余金の配当(増配)に関するお知らせ
05/07	16:30 自己株式の取得及び自己株式立会外買付取引(ToSTNeT-3)による自己株式の買付並びに自己株式の消却に関するお知らせ
05/07	16:30 新中期5ヵ年経営計画「Beyond 80」について
05/07	3,795	3,835	3,750	3,810	+0.4%	115,200	1825億4161万	+2.47%
05/02	3,795	3,830	3,775	3,795	0%	75,200	1818億2294万	+1.99%
05/01	3,770	3,795	3,750	3,795	+1.34%	61,300	1818億2294万	+1.82%
04/30	3,750	3,755	3,705	3,745	+1.22%	76,800	1794億2738万	+0.38%
04/28	3,715	3,745	3,690	3,700	-0.67%	66,500	1772億7138万	-0.96%
04/25	3,780	3,795	3,720	3,725	-1.32%	38,900	1784億6916万	-0.48%
04/24	3,850	3,895	3,775	3,775	-1.82%	67,700	1808億6472万	+0.75%
04/23	3,850	3,860	3,815	3,845	+0.26%	58,200	1842億1850万	+2.53%
04/22	3,790	3,890	3,785	3,835	+1.46%	77,000	1837億3939万	+2.29%
04/21	3,730	3,795	3,715	3,780	+1.89%	58,800	1811億427万	+0.85%
04/18	3,650	3,740	3,615	3,710	+3.2%	73,000	1777億5049万	-1.01%
04/17	3,580	3,600	3,560	3,595	+0.42%	47,600	1722億4071万	-4.13%
04/16	3,635	3,645	3,560	3,580	-1.51%	71,700	1715億2204万	-4.64%
04/15	3,650	3,670	3,630	3,635	0%	38,900	1741億5715万	-3.22%
04/14	3,600	3,675	3,590	3,635	+2.68%	68,900	1741億5715万	-3.25%
04/11	3,540	3,550	3,480	3,540	-3.67%	86,000	1696億559万	-5.8%
04/10	3,660	3,695	3,630	3,675	+2.37%	130,400	1760億7360万	-2.39%
04/09	3,595	3,680	3,560	3,590	-1.64%	107,600	1720億115万	-4.67%
04/08	3,690	3,690	3,575	3,650	+0.83%	118,800	1748億7582万	-3.16%
04/07	3,505	3,715	3,505	3,620	-2.56%	194,300	1734億3848万	-4%
04/04	3,835	3,835	3,705	3,715	-1.33%	156,200	1779億9005万	-1.54%
04/03	3,645	3,800	3,630	3,765	-0.13%	101,300	1803億8561万	-0.16%
04/02	3,805	3,810	3,740	3,770	-1.18%	66,600	1806億2516万	+0.13%
04/01	3,865	3,865	3,805	3,815	-0.78%	63,300	1827億8117万	+1.46%
03/31	3,845	3,880	3,755	3,845	-1.16%	99,000	1842億1850万	+2.51%
03/28	3,930	3,940	3,875	3,890	-1.14%	88,900	1863億7450万	+3.96%
03/27	3,880	3,940	3,875	3,935	+0.77%	125,900	1885億3051万	+5.47%
03/26	3,865	3,910	3,855	3,905	+0.64%	78,300	1870億9317万	+5%
03/25	3,865	3,890	3,805	3,880	+0.39%	61,600	1858億9539万	+4.64%
03/24	3,840	3,880	3,825	3,865	+1.05%	53,200	1851億7673万	+4.49%
03/21	3,800	3,840	3,800	3,825	-0.52%	55,200	1832億6028万	+3.6%
03/19	3,755	3,860	3,755	3,845	+0.52%	83,700	1842億1850万	+4.43%
03/18	3,825	3,870	3,800	3,825	+0.26%	76,800	1832億6028万	+4.08%
03/17	3,750	3,815	3,695	3,815	+1.33%	60,200	1827億8117万	+3.95%
03/14	3,730	3,785	3,730	3,765	0%	58,100	1803億8561万	+2.7%
03/13	3,710	3,800	3,705	3,765	+1.76%	69,300	1803億8561万	+2.76%
03/12	3,555	3,715	3,555	3,700	+2.21%	76,600	1772億7138万	+1.01%
03/11	3,640	3,660	3,565	3,620	-1.23%	93,600	1734億3848万	-1.47%
03/10	3,680	3,685	3,620	3,665	-0.14%	53,100	1755億9449万	-0.62%
03/07	3,685	3,700	3,650	3,670	-1.34%	45,700	1758億3404万	-0.81%
03/06	3,710	3,765	3,695	3,720	+0.54%	70,100	1782億2960万	+0.22%
03/05	3,710	3,750	3,670	3,700	+1.23%	65,300	1772億7138万	-0.64%
03/04	3,700	3,730	3,650	3,655	-0.95%	52,300	1751億1538万	-2.17%
03/03	3,735	3,745	3,690	3,690	+0.27%	47,500	1767億9227万	-1.47%
02/28	3,670	3,715	3,630	3,680	+0.41%	108,000	1763億1316万	-1.92%
02/27	3,650	3,675	3,625	3,665	+1.24%	64,500	1755億9449万	-2.5%
02/26	15:30 GnRHアンタゴニスト「リンザゴリクス」の子宮筋腫を適応症とした国内製造販売承認申請のお知らせ
02/26	3,595	3,660	3,570	3,620	-0.41%	47,200	1734億3848万	-3.9%
02/25	3,570	3,650	3,545	3,635	+1.25%	82,900	1741億5715万	-3.73%
02/21	3,640	3,640	3,515	3,590	-1.1%	60,500	1720億115万	-5.15%
02/20	3,595	3,700	3,595	3,630	+0.83%	77,900	1739億1760万	-4.35%
02/19	3,605	3,630	3,595	3,600	-1.5%	31,400	1724億8026万	-5.39%
02/18	3,625	3,665	3,620	3,655	+0.69%	22,000	1751億1538万	-4.44%
02/17	3,660	3,680	3,620	3,630	-0.68%	22,600	1739億1760万	-5.52%
02/14	3,660	3,685	3,640	3,655	-0.81%	29,600	1751億1538万	-5.36%
02/13	3,620	3,720	3,600	3,685	+3.08%	59,700	1765億5271万	-5.05%
02/12	3,665	3,670	3,560	3,575	-2.19%	54,200	1712億8248万	-8.36%
02/10	3,705	3,705	3,650	3,655	-1.48%	55,300	1751億1538万	-6.88%
02/07	3,715	3,735	3,695	3,710	-0.27%	57,600	1777億5049万	-5.96%
02/06	3,715	3,745	3,705	3,720	+0.4%	74,200	1782億2960万	-6.13%
02/05	3,750	3,800	3,665	3,705	-1.2%	133,800	1775億1094万	-6.75%
02/04	3,835	3,845	3,675	3,750	-5.66%	292,100	1796億6694万	-5.9%
02/03	15:30 2025年3月期第3四半期決算補足資料
02/03	15:30 2025年3月期第3四半期決算短信〔日本基準〕(連結)
02/03	3,950	3,980	3,930	3,975	+0.38%	111,200	1904億4696万	-0.05%
01/31	3,975	4,005	3,960	3,960	-0.38%	59,700	1897億2829万	+0.03%
01/30	3,960	3,995	3,960	3,975	+0.25%	102,000	1904億4696万	+0.91%
01/29	3,980	4,015	3,960	3,965	-1.12%	84,400	1899億6784万	+1.15%
01/28	4,020	4,075	3,975	4,010	+0.12%	76,600	1921億2385万	+2.77%
01/27	3,925	4,040	3,855	4,005	+2.82%	155,100	1918億8429万	+3.17%
01/24	3,885	3,915	3,840	3,895	+0.78%	71,200	1866億1406万	+0.83%
01/23	3,815	3,875	3,800	3,865	+0.26%	93,100	1851億7673万	+0.42%
01/22	3,885	3,890	3,850	3,855	0%	59,200	1846億9761万	+0.42%
01/21	11:30 脾臓チロシンキナーゼ阻害剤「ホスタマチニブ」の韓国における販売承認取得のお知らせ
01/21	3,855	3,890	3,840	3,855	+0.26%	55,200	1846億9761万	+0.73%
01/20	3,900	3,925	3,835	3,845	-0.39%	64,000	1842億1850万	+0.76%
01/17	3,845	3,955	3,840	3,860	+0.52%	125,100	1849億3717万	+1.45%
01/16	3,900	3,975	3,840	3,840	-1.03%	136,200	1839億7895万	+1.24%
01/15	4,025	4,075	3,880	3,880	-5.25%	253,500	1858億9539万	+2.54%
01/14	11:30 「ミニリンメルト」及び「デスモプレシン製剤」の国内販売提携終了に関するお知らせ
01/14	4,060	4,110	4,005	4,095	0%	109,000	1961億9630万	+8.45%
01/10	4,050	4,140	4,035	4,095	-0.36%	113,000	1961億9630万	+8.88%
01/09	4,110	4,230	4,090	4,110	-0.72%	148,800	1969億1497万	+9.75%
01/08	4,150	4,175	4,100	4,140	-0.84%	139,000	1983億5230万	+11.08%
01/07	15:30 脾臓チロシンキナーゼ阻害剤「ホスタマチニブ」の台田薬品(台湾)への技術導出契約締結のお知らせ
01/07	4,200	4,270	4,175	4,175	0%	127,900	2000億2919万	+12.66%
01/06	4,180	4,225	4,140	4,175	+0.36%	242,800	2000億2919万	+13.33%
2024
12/30	4,170	4,185	4,120	4,160	-0.24%	162,200	1993億1052万	+13.54%
12/27	3,985	4,185	3,980	4,170	+4.91%	281,400	1997億8964万	+14.5%
12/26	3,990	4,035	3,920	3,975	-0.63%	227,900	1904億4696万	+9.78%
12/25	3,600	4,000	3,600	4,000	+12.52%	359,700	1916億4474万	+10.8%
12/24	3,520	3,555	3,515	3,555	+0.99%	44,700	1703億2426万	-1.2%
12/23	3,485	3,550	3,485	3,520	+2.18%	62,200	1686億4737万	-2.25%
12/23	8:45 GnRHアンタゴニスト「イセルティ」(一般名リンザゴリクス)の欧州における子宮内膜症の追加適応症の取得について
12/20	3,530	3,535	3,445	3,445	-1.85%	90,100	1650億5403万	-4.44%

4547 キッセイ薬品工業

IR情報

2024/12/20～2025/05/23

IR情報＆株価推移

開示資料

決算

株式

チャート